Onesource Specialty Pharma Ltd
Onesource Specialty Pharma Ltd (ONESOURCE) last reported results for the quarter ended Jun 2026, with sales of ₹449 crore and net profit of ₹25 crore. The stock last traded at ₹1,506, a market capitalisation of ₹17,268 crore. Over the past 52 weeks the stock has ranged between ₹1,057 and ₹1,925. Figures are as of 6 Oct 2026 and are not real time.
Onesource Specialty Pharma Ltd share price and key metrics
- Current price
- ₹1,506
- Market cap
- ₹17,268 cr
- Book value
- ₹509
- ROE
- -1.09%
- ROCE
- 0.59%
- Dividend yield
- 0.00%
- 52w high / low
- 1925/1057
Metrics as of 6 Oct 2026. Not real time.
Track Onesource Specialty Pharma Ltd
Cruxal reads every Onesource Specialty Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Onesource Specialty Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 131%
- 3 Years
- 232%
- TTM
- 4%
- 10 Years
- %
- 5 Years
- 8%
- 3 Years
- 24%
- TTM
- -142%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- -21%
- 10 Years
- %
- 5 Years
- -10%
- 3 Years
- -3%
- Last Year
- -1%
Onesource Specialty Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹449 cr, up 37.3% from ₹327 cr a year earlier.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Expenses | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 |
| Operating profit | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 |
| OPM % | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% |
| Other income | -1 | -94 | 2 | 2 | 3 | -2 | 2 | -0 |
| Interest | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 |
| Depreciation | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 |
| Profit before tax | -37 | -67 | 83 | -4 | 6 | -93 | -0 | 20 |
| Tax % | 12% | 4% | -19% | -96% | -83% | -5% | -1,630% | -23% |
| Net profit | -42 | -69 | 98 | -0 | 10 | -89 | 5 | 25 |
| EPS (₹) | — | -6.02 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 | 2.18 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Onesource Specialty Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 21 | 132 | 39 | 172 | 1,445 | 1,422 | 1,543 |
| Operating profit | -71 | -97 | -161 | -82 | 467 | 304 | 339 |
| OPM % | -334% | -73% | -415% | -48% | 32% | 21% | 22% |
| Net profit | -121 | -231 | -800 | -391 | -18 | -74 | -49 |
| EPS (₹) | — | — | — | — | -1.57 | -6.44 | -4.24 |
TTM is the trailing twelve months to the most recent quarter.
Onesource Specialty Pharma Ltd balance sheet
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| Borrowings | 386 | 1,154 | 864 | 562 | 772 | 1,276 |
| Other liabilities | 96 | 276 | 365 | 468 | 1,005 | 1,197 |
| Total liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 |
| Fixed assets | 633 | 1,231 | 1,361 | 863 | 6,118 | 6,017 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 529 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| Other assets | 195 | 722 | 314 | 356 | 1,305 | 1,742 |
| Total assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 |
As reported by the company. Total assets equal total liabilities by construction.
Onesource Specialty Pharma Ltd cash flow
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -118 | -416 | -163 | -107 | -68 | 9 |
| Cash from investing | -207 | -692 | -68 | 511 | -201 | -495 |
| Cash from financing | 381 | 1,162 | 118 | -391 | 412 | 359 |
| Net cash flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free cash flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO / operating profit | 164% | 430% | 108% | 130% | -13% | 6% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Onesource Specialty Pharma Ltd operating ratios
| Per year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ROCE % | — | -10% | -12% | -12% | 6% | 1% |
| Debtor days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory days | 87 | 1,805 | 615 | 258 | 222 | 438 |
| Days payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash conversion cycle | -637 | 1,461 | 232 | 212 | 180 | 308 |
| Working capital days | -2,392 | -1,291 | -6,745 | -877 | -58 | -6 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Onesource Specialty Pharma Ltd shareholding pattern
Promoters held 30.48% at Jun 2026, up from 29.78% at Jun 2025. FIIs 19.19% and DIIs 23.37%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Promoters | 37.76% | 34.25% | 29.78% | 29.77% | 29.93% | 30.48% | 30.48% |
| FIIs | 17.44% | 18.54% | 18.69% | 19.39% | 19.24% | 17.50% | 19.19% |
| DIIs | 12.56% | 18.03% | 18.09% | 18.48% | 18.80% | 20.61% | 23.37% |
| Public | 32.24% | 29.17% | 33.42% | 32.34% | 32.01% | 31.40% | 26.95% |
| No. of shareholders | 98,425 | 82,712 | 87,760 | 87,416 | 84,595 | 79,460 | 77,899 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Onesource Specialty Pharma Ltd corporate filings
- Onesource Specialty Pharma Ltd allots 900 equity shares under ESOP 2021Company Updatelow impact
Cruxal's analysis: Onesource Specialty Pharma Ltd has allotted 900 equity shares of Re. 1 each on September…
Read the full analysis - Closure of trading window for the quarter ended September 30, 2026Insider Trading / SASTlow impact
- OneSource Specialty Pharma Limited Announces Successful Conclusion of 19th Annual General Meeting and Shareholder Approval of Related Party TransactionsAGM/EGMlow impact
Cruxal's analysis: OneSource Specialty Pharma Limited has successfully concluded its 19th Annual General…
Read the full analysis - OneSource Specialty Pharma Limited Appoints B S R & Co LLP as Statutory AuditorsCompany Updatelow impact
Cruxal's analysis: OneSource Specialty Pharma Limited has formally appointed M/s B S R & Co LLP as its…
Read the full analysis - OneSource Specialty Pharma Limited Concludes 19th Annual General Meeting; Approves Key Financial and Governance ResolutionsAGM/EGMlow impact
Cruxal's analysis: OneSource Specialty Pharma Limited successfully held its 19th Annual General Meeting on…
Read the full analysis - OneSource Specialty Pharma Issues Addendum to 19th AGM Notice Regarding Related Party TransactionsCompany Updatelow impact
Cruxal's analysis: OneSource Specialty Pharma Limited has issued an addendum to its 19th Annual General…
Read the full analysis - OneSource Specialty Pharma Limited files investor presentation for facility visitCompany Updatelow impact
Cruxal's analysis: OneSource Specialty Pharma Limited has formally filed its latest investor presentation in…
Read the full analysis - OneSource Specialty Pharma Limited Announces Dispatch of Notice for 19th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: OneSource Specialty Pharma Limited has formally confirmed the completion of the dispatch…
Read the full analysis - OneSource Specialty Pharma Limited Announces 19th AGM and Releases Integrated Annual Report for FY 2025-26AGM/EGMlow impact
Cruxal's analysis: OneSource Specialty Pharma Limited has scheduled its 19th Annual General Meeting for…
Read the full analysis - Onesource Specialty Pharma Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2026Otherslow impact
Cruxal's analysis: Onesource Specialty Pharma Ltd has submitted its Business Responsibility and…
Read the full analysis - Onesource Specialty Pharma Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Onesource Specialty Pharma Ltd has filed its Annual Report for the financial year…
Read the full analysis - Onesource Specialty Pharma Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Onesource Specialty Pharma Ltd has filed its Annual Report for the financial year…
Read the full analysis - Onesource Specialty Pharma Ltd schedules investor meeting for September 03, 2026Company Updatelow impact
Cruxal's analysis: Onesource Specialty Pharma Ltd has announced an investor meeting scheduled for September…
Read the full analysis - Onesource Specialty Pharma Ltd announces 19th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Onesource Specialty Pharma Ltd has issued a newspaper advertisement regarding the…
Read the full analysis - OneSource Specialty Pharma Receives Credit Rating Upgrade to IND A/Positive by India RatingsCompany Updatemedium impact
Cruxal's analysis: OneSource Specialty Pharma Limited has secured a credit rating upgrade to 'IND A' with a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.